Patents by Inventor Karin Jooss

Karin Jooss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090130054
    Abstract: The present invention relates to a method of enhancing anti-tumor protection in a mammal. More particularly, the invention is concerned with combinations comprising antigen presenting cell (APC) activators and a cytokine-secreting cell and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.
    Type: Application
    Filed: August 29, 2008
    Publication date: May 21, 2009
    Applicants: Cell Genesys, Inc., Immutep S.A.
    Inventors: Karin Jooss, Betty Li, Frederic Triebel
  • Patent number: 7498024
    Abstract: Single vector constructs for expression of an immunoglobulin molecule or fragment thereof and methods of making and using the same are described. The vectors comprise a self-processing cleavage sequence between a first and second immunoglobulin coding sequence allowing for expression of a functional antibody molecule using a single promoter. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from an expressed immunoglobulin molecule or fragment thereof. The vector constructs find utility in methods for enhanced production of biologically active immunoglobulins or fragments thereof in vitro or in vivo.
    Type: Grant
    Filed: April 26, 2004
    Date of Patent: March 3, 2009
    Assignee: Cell Genesys, Inc.
    Inventors: Jianmin Fang, Karin Jooss, Jing-Jing Qian
  • Publication number: 20090053750
    Abstract: The present invention relates to filamin-B peptides, compositions comprising such peptides, and methods of using such peptides to assess an immune response against such peptides. An immune response against the peptides correlates with an immune response, in particular a cellular immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.
    Type: Application
    Filed: July 26, 2007
    Publication date: February 26, 2009
    Applicant: Cell Genesys, Inc.
    Inventors: Jooeun Bae, Karin Jooss
  • Patent number: 7485291
    Abstract: Single vector constructs for expression of a functional antibody molecule are described. The vectors have a self-processing cleavage site between two heterologous DNA coding sequences allowing for expression of two coding sequences using a single promoter. Exemplary vector constructs comprise a foot and mouth disease virus (FMDV) 2A sequence. The vector constructs can be used in methods relating to antibody delivery and therapy and in the production of a biologically active antibody or fragment thereof.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: February 3, 2009
    Assignee: Cell Genesys, Inc.
    Inventors: Jianmin Fang, Karin Jooss, Jing-Jing Qian
  • Publication number: 20090028857
    Abstract: The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.
    Type: Application
    Filed: July 23, 2008
    Publication date: January 29, 2009
    Applicant: CELL GENESYS, INC.
    Inventors: Betty Li, Karin Jooss, Alan J. Korman
  • Publication number: 20080280356
    Abstract: Vector constructs for expression of two or more functional proteins or polypeptides under operative control of a single promoter and methods of making and using the same are described. The vectors comprise a self-processing cleavage site between each respective protein or polypeptide coding sequence. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from expressed protein(s) or polypeptide(s). The vector constructs find utility in methods for enhanced production of biologically active proteins and polypeptides in vitro and in vivo.
    Type: Application
    Filed: October 26, 2007
    Publication date: November 13, 2008
    Applicant: Cell Genesys, Inc.
    Inventors: Jianmin Fang, Karin Jooss, Andrew Simmons, Jing-Jing Qian
  • Publication number: 20080279831
    Abstract: The present invention relates to prostate cancer markers, compositions comprising such markers, immunoglobulins specific for such markers, and methods of using such markers and/or immunoglobulins to assess an immune response against prostate cancer. An immune response against the markers correlates with an immune response, in particular a humoral immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.
    Type: Application
    Filed: March 3, 2008
    Publication date: November 13, 2008
    Applicant: Cell Genesys, Inc.
    Inventors: Karin Jooss, Thomas Harding, Minh Nguyen, Kathryn E. Koprivnikar
  • Publication number: 20080267935
    Abstract: The present invention provides improved method of cancer therapy in a mammal. More particularly, the invention is concerned with systems comprising cytosine arabinoside (AraC) and a cytokine-expressing cancer immunotherapy composition and methods of administering the combination to cancer patients in order to generate an immune response against the cancer and provide treatment with therapeutic efficacy that is an improvement relative to administration of AraC or the cytokine-expressing cancer immunotherapy composition alone as a monotherapy.
    Type: Application
    Filed: April 4, 2008
    Publication date: October 30, 2008
    Applicant: Cell Genesys, Inc.
    Inventors: JianMin Lin, Betty Li, Eric Rimmer, Melinda Van Roey, Karin Jooss
  • Publication number: 20080014222
    Abstract: Cellular compositions and methods for inducing an immune response to tumor cells are described. The cellular compositions include a tumor antigen and cells that have been modified to express a cytokine and one or more of a tumor antigen, anti-CTLA4 antibody and an additional cytokine. The cellular compositions find utility in methods for treating cancer.
    Type: Application
    Filed: March 28, 2007
    Publication date: January 17, 2008
    Applicants: Cell Genesys, Inc., The Reagents of the University of California
    Inventors: Andrew Simmons, Karin Jooss, James Allison
  • Publication number: 20070292922
    Abstract: Single AAV vector constructs for regulated expression of an immunoglobulin molecule or fragment thereof and methods of making and using the same are described. The AAV vectors comprise a regulated promoter operably linked to the coding sequence for a first and second immunoglobulin coding sequence, a sequence encoding a self-processing cleavage site between the coding sequence for the first and second immunoglobulin coding sequence and a additional proteolytic cleavage site, which provides a means to remove the self processing peptide sequence from an expressed immunoglobulin molecule or fragment thereof. The vector constructs find utility in enhanced production of biologically active immunoglobulins or fragments thereof in vitro and in vivo.
    Type: Application
    Filed: March 28, 2007
    Publication date: December 20, 2007
    Applicants: Cell Genesys, Inc., ARIAD Pharmaceuticals, Inc.
    Inventors: Jianmin Fang, Karin Jooss, Minh Nguyen, Thomas Harding, Timothy Clackson, Victor Rivera
  • Publication number: 20070231298
    Abstract: The present invention in all of its associated aspects provides improved methods and compositions for treating cancer in a mammal based on the sequential administration of the combination of a cytokine-expressing cancer immunotherapy composition and at least one tyrosine kinase inhibitor, wherein administration of the combination results in enhanced therapeutic efficacy relative to administration of the cytokine-expressing cancer immunotherapy composition or at least one tyrosine kinase inhibitor as a monotherapy.
    Type: Application
    Filed: March 27, 2007
    Publication date: October 4, 2007
    Applicant: Cell Genesys, Inc.
    Inventors: Betty Li, Thomas Du, Karin Jooss
  • Publication number: 20070059820
    Abstract: Lentivector constructs for expression of recombinant proteins, polypeptides or fragments thereof and methods of making the same are described. The lentivectors typically have a self-processing cleavage sequence between a first and second protein or polypeptide coding sequence allowing for expression of a functional protein or polypeptide under operative control of a single promoter and may further include an additional proteolytic cleavage sequence which provides a means to remove the self-processing cleavage sequence from the expressed protein or polypeptide. The vector constructs find utility in methods relating to enhanced production of biologically active proteins, such as immunoglobulins or fragments thereof in vitro and in vivo.
    Type: Application
    Filed: July 18, 2006
    Publication date: March 15, 2007
    Inventors: Jianmin Fang, Karin Jooss, Andrew Simmons, Debbie Farson
  • Patent number: 7186699
    Abstract: The present invention provides therapeutic compositions and methods for vector-mediated delivery and in vivo expression of polynucleotides encoding anti-cancer compounds that are effective in the treatment of cancer. In particular, the invention relates to the use of recombinant viral and non-viral vectors to deliver genes encoding one or more anti-angiogenic or proapoptotic gene products for the treatment of cancer.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: March 6, 2007
    Assignee: Cell Genesys, Inc.
    Inventors: Thomas Harding, Karin Jooss, Alshad Lalani, Brian Donahue
  • Publication number: 20060034805
    Abstract: Single AAV vector constructs for expression of an immunoglobulin molecule or fragment thereof and methods of making and using the same are described. The AAV vectors comprise a self-processing cleavage sequence between a first and second immunoglobulin coding sequence allowing for expression of a functional antibody molecule using a single promoter. The vector constructs may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from an expressed immunoglobulin molecule or fragment thereof. The vector constructs find utility in enhanced production of biologically active immunoglobulins or fragments thereof in vitro and in vivo.
    Type: Application
    Filed: July 13, 2005
    Publication date: February 16, 2006
    Inventors: Jianmin Fang, Karin Jooss
  • Publication number: 20050042721
    Abstract: Vector constructs for expression of two or more functional proteins or polypeptides under operative control of a single promoter and methods of making and using the same are described. The vectors comprise a self-processing cleavage site between each respective protein or polypeptide coding sequence. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from expressed protein(s) or polypeptide(s). The vector constructs find utility in methods for enhanced production of biologically active proteins and polypeptides in vitro and in vivo.
    Type: Application
    Filed: April 26, 2004
    Publication date: February 24, 2005
    Inventors: Jianmin Fang, Karin Jooss, Andrew Simmons, Jing-Jing Qian
  • Publication number: 20050031593
    Abstract: The present invention provides therapeutic compositions and methods for vector-mediated delivery and in vivo expression of polynucleotides encoding anti-cancer compounds that are effective in the treatment of cancer. In particular, the invention relates to the use of recombinant viral and non-viral vectors to deliver genes encoding one or more anti-angiogenic or proapoptotic gene products for the treatment of cancer.
    Type: Application
    Filed: May 28, 2004
    Publication date: February 10, 2005
    Inventors: Thomas Harding, Karin Jooss, Alshad Lalani, Brian Donahue
  • Publication number: 20050003482
    Abstract: Single vector constructs for expression of an immunoglobulin molecule or fragment thereof and methods of making and using the same are described. The vectors comprise a self-processing cleavage sequence between a first and second immunoglobulin coding sequence allowing for expression of a functional antibody molecule using a single promoter. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from an expressed immunoglobulin molecule or fragment thereof. The vector constructs find utility in methods for enhanced production of biologically active immunoglobulins or fragments thereof in vitro or in vivo.
    Type: Application
    Filed: April 26, 2004
    Publication date: January 6, 2005
    Inventors: Jianmin Fang, Karin Jooss, Jing-Jing Qian
  • Publication number: 20050002916
    Abstract: The present invention in all of its associated aspects provides improved methods and compositions for treating cancer in a mammal based on the administration of the combination of a cytokine-expressing cellular vaccine and at least one additional cancer therapeutic agent or treatment to a patient with cancer, wherein administration of the combination results in enhanced therapeutic efficacy relative to administration of the cytokine-expressing cellular vaccine or cancer therapeutic agent or treatment as a monotherapy.
    Type: Application
    Filed: March 24, 2004
    Publication date: January 6, 2005
    Inventors: Karin Jooss, Jennifer Creson, Betty Li, Rodney Prell, Sandra Aung, Marina Moskalenko, Thomas Du
  • Publication number: 20040265955
    Abstract: Single vector constructs for expression of a functional antibody molecule are described. The vectors have a self-processing cleavage site between two heterologous DNA coding sequences allowing for expression of two coding sequences using a single promoter. Exemplary vector constructs comprise a foot and mouth disease virus (FMDV) 2A sequence. The vector constructs can be used in methods relating to antibody delivery and therapy and in the production of a biologically active antibody or fragment thereof.
    Type: Application
    Filed: June 3, 2003
    Publication date: December 30, 2004
    Inventors: Jianmin Fang, Karin Jooss, Jing-Jing Qian
  • Publication number: 20040197312
    Abstract: The present invention in all of its associated aspects provides improved methods and compositions for treating cancer in a mammal based on the administration of the combination of a cytokine-expressing cellular vaccine and at least one additional cancer therapeutic agent or treatment to a patient with cancer, wherein administration of the combination results in enhanced therapeutic efficacy relative to administration of components thereof as a monotherapy.
    Type: Application
    Filed: April 2, 2003
    Publication date: October 7, 2004
    Inventors: Marina Moskalenko, Betty Li, Sandra Aung, Rodney Prell, Jennifer Creson, Karin Jooss